All‐cause mortality · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes mortality compared with rituximab (very low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes remission compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.44 [0.11, 1.81]
Studies not reported
Very low
Durable remission during additional · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes durable remission during additional compared with rituximab (very low certainty).
1 finding from 1 review
RR 0.22 [0.03, 1.6]
Studies not reported
Very low
Flare‐ups or relapse (continuous) · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any severe AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 1.78 [0.2, 16.1]
Studies not reported
Very low
Withdrawals due to adverse events · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any withdrawals due to AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 2.7 [0.13, 58.24]
Studies not reported
Very low
Intervention not reported
The annualised rate of relapse Scale from: 0 to infinity. · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
The sum of the number of gadolinium‐enhancing T1‐weighted lesions Scale from: 0 to infinity. · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
The number of patients with adverse effects · patients with relapsing‐remitting multiple sclerosis
The intervention showed no clear difference in the number of patients with adverse effects (low certainty).
1 finding from 1 review
Intervention not reported
The number of patients with serious adverse events · patients with relapsing‐remitting multiple sclerosis
The intervention showed no clear difference in the number of patients with serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
The number of patients who withdrew or dropped out from the study because of AEs · patients with relapsing‐remitting multiple sclerosis
The intervention showed no clear difference in the number of patients who withdrew or dropped out from the study… (low certainty).
1 finding from 1 review
Intervention not reported
The number of patients with disability progression · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
The time to confirmed disease progression · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Intervention not reported
OS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention leads to lower OS (at 3 years) (high certainty).
1 finding from 1 review
Intervention not reported
TRM · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in TRM (low certainty).
1 finding from 1 review
Intervention not reported
PFS (at 3 years) · newly diagnosed or relapsed patients with CLL
The intervention probably leads to lower PFS (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
TRM · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in TRM (moderate certainty).
1 finding from 1 review
Intervention not reported
SAEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL
The intervention showed no clear difference in SAEs ‐ overall analysis (low certainty).
1 finding from 1 review
Intervention not reported
Grade 3/4 AEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL
The intervention probably leads to higher grade 3/4 AEs ‐ overall analysis (moderate certainty).
1 finding from 1 review